LONDON — Novartis on Tuesday increased its earnings guidance for the third time this year, boosted by strong sales of its leading drugs.
The company said it anticipates full-year operating profit to grow by a percentage in the high teens, up from the previously forecasted mid- to high teens.
Separately, Novartis CEO Vas Narasimhan said it would be a “couple more years” before the company could submit to regulators an experimental drug for a rare bone marrow cancer that was the centerpiece of a nearly $3 billion deal. Novartis had originally hoped to file for the drug’s approval this year, but ongoing questions about its data profile have yet to be resolved.
Click this link for the original source of this article.
Author: Andrew Joseph
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.